Funding for this research was provided by:
Janssen Global Services, LLC
Received: 10 May 2020
Accepted: 6 October 2020
First Online: 10 November 2020
Ethics approval and consent to participate
: As the databases used contain only retrospective data, and since patients are not identifiable, approval and written informed consent by patients or Institutional Review Board/Independent Ethical Committee approvals are not required.
: Not applicable.
: Rafael Fonseca served as a consultant for AbbVie, Aduro, Amgen, Bayer, BMS/Celgene, GlaxoSmithKline, Janssen, Juno, Kite, Merck, Novartis, Oncotracker, Pharmacyclics, and Sanofi; and participated in an advisory board for Adaptive Biotechnologies. Saad Z. Usmani served as a consultant/advisor for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck, SkylineDx, and Takeda; participated in a Speakers Bureau for Amgen, Celgene, Janssen, Sanofi, and Takeda; and received research grants from Amgen, Array Biopharma, Bristol-Myers Squibb, Celgene, Janssen, Merck, Pharmacyclics, Sanofi, and Takeda. Maneesha Mehra, Mary Slavcev, Jianming He, Sarah Cote, Annette Lam, Jon Ukropec, and Sandhya Nair are employees of Janssen. Eric M. Maiese was an employee of Janssen at the time the study was conducted. Ravi Potluri is an employee of SmartAnalyst Inc. Peter M. Voorhees received research funding from Amgen, Celgene, GlaxoSmithKline, Janssen, and Takeda; and served as a consultant/advisor for Adaptive Biotechnologies, Bristol-Myers Squibb, Celgene, Janssen, Novartis, Oncopeptides, Takeda, and TeneBio.